<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 27, 2025</title>
<meta name="color-scheme" content="light" />
<style>
  :root { --maxw: 800px; color-scheme: light; }
  html { -webkit-text-size-adjust: 100%; }
  body {
    margin: 0;
    padding: 0;
    background-color: #ffffff;
    color: #111111;
    font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji;
    line-height: 1.6;
    font-size: 18px;
  }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

Los <span title="bispecific antibodies">anticuerpos biespecíficos</span> que <span title="activate T cells">activan células T</span> ahora <span title="are used not only">se usan no solo</span> para la <span title="relapse">recaída</span>, sino también <span title="earlier in therapy">más temprano en la terapia</span> para niños con <span title="B-cell acute lymphoblastic leukemia">leucemia linfoblástica aguda de células B</span> (LLA-B). Nuevos datos de <span title="phases 2–3">fases 2–3</span> <span title="drive this change">impulsan este cambio</span>.

Blinatumomab: En el <span title="phase 3 study">estudio fase 3</span> COG AALL1731, <span title="adding blinatumomab">agregar blinatumomab</span> a la <span title="first remission therapy">terapia de primera remisión</span> de alto riesgo en niños y adultos jóvenes con LLA-B <span title="resulted in">resultó en</span> una mejor <span title="event-free survival">supervivencia libre de eventos</span> y <span title="overall survival">supervivencia global</span> en comparación con la <span title="chemotherapy alone">quimioterapia sola</span> (Brown et al., N Engl J Med 2024).

Seguridad/uso temprano: En AALL1731, <span title="blinatumomab was given">blinatumomab se administró</span> temprano en la <span title="consolidation phase">consolidación</span>. Las <span title="rates of cytokine release syndrome">tasas de síndrome de liberación de citocinas</span> y <span title="grade 3 or higher neurotoxicity">neurotoxicidad de grado ≥3</span> <span title="were low">fueron bajas</span>. El <span title="transfer to ICU">traslado a UCI</span> no <span title="was not common">fue común</span>. Su <span title="use is better">uso es mejor</span> en <span title="centers with experience and training">centros con experiencia y capacitación</span>.

Desescalada de quimioterapia: En AALL1731, la <span title="survival was better">supervivencia fue mejor</span> incluso con <span title="less intensive chemotherapy">quimioterapia menos intensiva</span>. Esto <span title="means that">significa que</span> los <span title="bispecific antibodies">anticuerpos biespecíficos</span> <span title="can replace part of">pueden reemplazar parte de</span> la <span title="cytotoxic therapy">terapia citotóxica</span> sin <span title="worse outcomes">peores resultados</span>.

Toma de decisiones sobre trasplante: Muchos niños con <span title="positive MRD">ERM positiva</span> <span title="became MRD negative">se volvieron ERM negativa</span> con blinatumomab. Esto <span title="can change">puede cambiar</span> los <span title="plans for allogeneic stem cell transplant">planes para trasplante alogénico de células madre hematopoyéticas</span> en la <span title="first remission">primera remisión</span> cuando <span title="a deep molecular remission is achieved">se logra una remisión molecular profunda</span>.

Enfermedad en lactantes y de muy alto riesgo: Blinatumomab <span title="shows activity">muestra actividad</span> en <span title="infants with KMT2A rearrangement">lactantes con reordenamiento KMT2A</span> y otros <span title="very high-risk groups">grupos de muy alto riesgo</span>, pero los <span title="data are still limited">datos aún son limitados</span>.

Biespecíficos de nueva generación: <span title="new CD19×CD3 and CD20×CD3 agents">Nuevos agentes CD19×CD3 y CD20×CD3</span> <span title="show promising MRD-negative remissions">muestran remisiones ERM negativa prometedoras</span> en <span title="early phase 1–2 studies">estudios fase 1–2 tempranos</span>.

En la práctica, los <span title="pediatric B-ALL protocols">protocolos de LLA-B pediátrica</span> en <span title="first-line">primera línea</span> ahora <span title="add blinatumomab">agregan blinatumomab</span> para algunos <span title="high-risk and MRD-positive patients">pacientes de alto riesgo y ERM positiva</span>, y también <span title="reconsider the intensity">reconsideran la intensidad</span> de la <span title="chemotherapy">quimioterapia</span> y la <span title="need for transplant">necesidad de trasplante</span>.

---
DIALOGUE

Narrator: Hoy <span title="we talk about">hablamos sobre</span> un <span title="new treatment">nuevo tratamiento</span> para la <span title="B-cell acute lymphoblastic leukemia">leucemia linfoblástica aguda de células B</span> en niños.
Physician: Hola, <span title="I want to share">quiero compartir</span> <span title="new treatment options">nuevas opciones de tratamiento</span> para tu LLA-B.
Patient: ¿<span title="What is">Cuál es</span> el <span title="new treatment">nuevo tratamiento</span>?
Physician: <span title="It is called">Se llama</span> blinatumomab. <span title="It is a bispecific antibody">Es un anticuerpo biespecífico</span> que <span title="activates T cells">activa las células T</span>.
Patient: ¿<span title="Is this medicine">Este medicamento</span> <span title="better than chemotherapy">es mejor que la quimioterapia</span>?
Physician: Los <span title="studies show that">estudios muestran que</span> blinatumomab con <span title="less chemotherapy">menos quimioterapia</span> <span title="helps more children">ayuda a que más niños</span> <span title="live longer">vivan por más tiempo</span>.
Patient: ¿<span title="Does it have strong side effects">Tiene efectos secundarios fuertes</span>?
Physician: La <span title="majority of children">mayoría de los niños</span> no <span title="have serious side effects">presenta efectos secundarios graves</span>, como <span title="cytokine release syndrome">síndrome de liberación de citocinas</span> o <span title="neurotoxicity">neurotoxicidad</span>.
Patient: ¿<span title="Do I still need a transplant">Todavía necesito un trasplante</span>?
Physician: Muchos niños <span title="become MRD negative">se vuelven ERM negativa</span> después de blinatumomab, <span title="so some do not need">así que algunos no necesitan</span> trasplante.
Patient: ¿<span title="Does this medicine help">Este medicamento ayuda</span> si mi <span title="leukemia is very high risk">leucemia es de muy alto riesgo</span>?
Physician: Sí, <span title="it can help">puede ayudar</span>, incluso en LLA-B con <span title="KMT2A rearrangement">reordenamiento KMT2A</span> o de <span title="high risk">alto riesgo</span>, pero <span title="we need more data">necesitamos más datos</span>.
Patient: ¿<span title="Is it safe to use">Es seguro usar</span> este medicamento <span title="early on">temprano</span>?
Physician: <span title="We administer">Administramos</span> blinatumomab <span title="early during consolidation">temprano durante la consolidación</span> y la <span title="majority of children">mayoría de los niños</span> <span title="do well">evoluciona bien</span>.
Patient: ¿<span title="Are even better medicines coming">Vienen medicamentos aún mejores</span>?
Physician: Sí, <span title="new bispecific antibodies are being studied">se están estudiando nuevos anticuerpos biespecíficos</span> CD19×CD3 y CD20×CD3.

    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Bispecific T-cell–engaging antibodies are now used not only for relapse but also earlier in therapy for children with B-cell acute lymphoblastic leukemia (B-ALL). New phase 2–3 data drive this change.

Blinatumomab: In the COG AALL1731 phase 3 trial, adding blinatumomab to high-risk first-remission therapy in children and young adults with B-ALL gave better event-free survival and overall survival than chemotherapy alone (Brown et al., N Engl J Med 2024).

Safety/early use: In AALL1731, blinatumomab was given early in consolidation. Rates of grade ≥3 cytokine release syndrome and neurotoxicity were low. ICU transfer was not common. Use is best in centers with experience and training.

Chemotherapy de-escalation: In AALL1731, survival was better even with less intensive chemotherapy. This means bispecific antibodies may replace some cytotoxic therapy without worse outcomes.

Transplant decision-making: Many MRD-positive children became MRD-negative with blinatumomab. This can change plans for allogeneic HSCT in first remission when deep molecular remission is reached.

Infant and very-high-risk disease: Blinatumomab shows activity in KMT2A-rearranged infants and other very-high-risk groups, but data are still limited.

Next-generation bispecifics: New CD19×CD3 and CD20×CD3 agents show promising MRD-negative remissions in early phase 1–2 trials.

In practice, frontline pediatric B-ALL protocols now add blinatumomab for some high-risk and MRD-positive patients and also rethink chemotherapy intensity and transplant needs.

---
DIALOGUE

Narrator: Today, we talk about new treatment for B-cell acute lymphoblastic leukemia in children. 
Physician: Hello, I want to share new treatment choices for your B-ALL. 
Patient: What is the new treatment? 
Physician: It is called blinatumomab. It is a bispecific T-cell–engaging antibody.
Patient: Is this medicine better than chemotherapy? 
Physician: Studies show blinatumomab with less chemotherapy helps more children live longer.
Patient: Does it have strong side effects? 
Physician: Most children do not get severe side effects, like cytokine release syndrome or neurotoxicity. 
Patient: Do I still need a transplant?
Physician: Many children become MRD-negative after blinatumomab, so some do not need a transplant.
Patient: Will this medicine help if my leukemia is very high risk? 
Physician: Yes, it can help, even in KMT2A-rearranged or high-risk B-ALL, but we need more data.
Patient: Is this medicine safe to use early? 
Physician: We give blinatumomab early during consolidation, and most children do well.
Patient: Are there even better medicines coming?
Physician: Yes, new CD19×CD3 and CD20×CD3 bispecific antibodies are being studied.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 27, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>